Evogene Statistics

Total Valuation

Evogene has a market cap or net worth of ILS 32.03 million. The enterprise value is 22.05 million.

Market Cap	32.03M
Enterprise Value	22.05M

Important Dates

The next estimated earnings date is Thursday, March 6, 2025.

Earnings Date	Mar 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Evogene has 6.79 million shares outstanding. The number of shares has increased by 21.07% in one year.

Current Share Class	n/a
Shares Outstanding	6.79M
Shares Change (YoY)	+21.07%
Shares Change (QoQ)	+14.07%
Owned by Insiders (%)	1.23%
Owned by Institutions (%)	8.55%
Float	6.70M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.89
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.25
EV / Sales	0.79
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.29

Financial Position

The company has a current ratio of 1.09, with a Debt / Equity ratio of 0.06.

Current Ratio	1.09
Quick Ratio	1.03
Debt / Equity	0.06
Debt / EBITDA	n/a
Debt / FCF	-0.03
Interest Coverage	-10.24

Financial Efficiency

Return on equity (ROE) is -105.55% and return on invested capital (ROIC) is -61.89%.

Return on Equity (ROE)	-105.55%
Return on Assets (ROA)	-31.64%
Return on Capital (ROIC)	-61.89%
Revenue Per Employee	195,760
Profits Per Employee	-615,527
Employee Count	142
Asset Turnover	0.15
Inventory Turnover	2.96

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -80.63% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-80.63%
50-Day Moving Average	661.38
200-Day Moving Average	1,615.60
Relative Strength Index (RSI)	24.79
Average Volume (20 Days)	31,582

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Evogene had revenue of ILS 27.80 million and -87.40 million in losses. Loss per share was -16.66.

Revenue	27.80M
Gross Profit	19.15M
Operating Income	-92.08M
Pretax Income	-94.37M
Net Income	-87.40M
EBITDA	-85.51M
EBIT	-92.08M
Loss Per Share	-16.66

Full Income Statement

Balance Sheet

The company has 74.17 million in cash and 2.55 million in debt, giving a net cash position of 71.62 million or 10.54 per share.

Cash & Cash Equivalents	74.17M
Total Debt	2.55M
Net Cash	71.62M
Net Cash Per Share	10.54
Equity (Book Value)	45.49M
Book Value Per Share	-2.38
Working Capital	7.70M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -75.90 million and capital expenditures -1.45 million, giving a free cash flow of -77.35 million.

Operating Cash Flow	-75.90M
Capital Expenditures	-1.45M
Free Cash Flow	-77.35M
FCF Per Share	-11.39

Full Cash Flow Statement

Margins

Gross Margin	68.90%
Operating Margin	-331.25%
Pretax Margin	-339.50%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Evogene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-21.07%
Shareholder Yield	-21.07%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

The last stock split was on July 28, 2024. It was a reverse split with a ratio of 0.1.

Last Split Date	Jul 28, 2024
Split Type	Reverse
Split Ratio	0.1

Scores

Evogene has an Altman Z-Score of -10.66. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-10.66
Piotroski F-Score	n/a